SCHEMBL7560067

SCHEMBL7560067

CC(C)c1c(C(=O)N/N=C\c2cccs2)[nH]c2ccccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.58
RAB9A P51151 8/20 0.58
SMN1; SMN2 Q16637 7/20 0.58
POLB P06746 4/20 0.58
PKM P14618 2/20 0.53
MAPT P10636 6/20 0.52
ALDH1A1 P00352 5/20 0.52
LMNA P02545 2/20 0.52
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
KDM4E B2RXH2 1/20 0.48
BLM P54132 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
CYP1A2 P05177 1/20 0.47
RECQL P46063 1/20 0.47
HTT P42858 2/20 0.46
TP53 P04637 1/20 0.46
HPGD P15428 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
THRB P10828 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7560072 1.00 NPC1 (0.58) NPC1RAB9ASMN1; SMN2POLBPKM
SCHEMBL7533746 0.83 SMN1; SMN2 (0.51) NPC1RAB9ASMN1; SMN2POLBMAPT
SCHEMBL7569598 0.83 SMN1; SMN2 (0.51) NPC1RAB9ASMN1; SMN2POLBMAPT
SCHEMBL7569693 0.83 RAB9A (0.61) NPC1RAB9ASMN1; SMN2POLBPKM
SCHEMBL7569698 0.83 RAB9A (0.61) NPC1RAB9ASMN1; SMN2POLBPKM
SCHEMBL7559728 0.83 SMN1; SMN2 (0.57) NPC1RAB9ASMN1; SMN2POLBPKM
SCHEMBL7559725 0.83 SMN1; SMN2 (0.57) NPC1RAB9ASMN1; SMN2POLBPKM
SCHEMBL7559993 0.82 MAPT (0.46) NPC1RAB9ASMN1; SMN2POLBPKM
SCHEMBL7559999 0.82 MAPT (0.46) NPC1RAB9ASMN1; SMN2POLBPKM
SCHEMBL7560877 0.82 RAB9A (0.59) NPC1RAB9ASMN1; SMN2POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US claimed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO claimed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US claimed
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US disclosed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO disclosed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors MKI67, FLT4, IDO1 NPC1 3749/4885RAB9A 3961/4885SMN1; SMN2 4745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.